Trial Profile
A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms PP-02
- Sponsors Pharmacosmos
- 18 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 28 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov
- 13 Jun 2014 New trial record